Wall St set for $1bn fee bonanza from pharma mega-deal
Drugmakers Bristol-Myers Squibb and Celgene will pay about $1bn in fees to seal their $90bn tie-up, including more than $300m to their financial advisers, in one of the most lucrative advisory assignments ever recorded on Wall Street. The fees will be split among a handful of investment banks, including Morgan Stanley, JPMorgan Chase and Citigroup,…
We want to hear from you all.
CLICK TO SEE OR ADD COMMENT